LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today the agenda for its virtual Capital Markets Day on 12 October 2022 at 8:00 am ET (1 pm UK).
Topics to be covered at the event span the design of the Phase 3 program for COMP360 psilocybin therapy in treatment-resistant depression (TRD), TRD treatment landscape, commercial strategy, digital tools, and pipeline. It will be hosted by the Company’s leadership team and will include leading key opinion leaders:
- Phyllis Foxworth, Depression and Bipolar Support Alliance
- Walter Kaye, MD, University of California, San Diego
- Charles Nemeroff, MD, PhD, The University of Texas at Austin, Dell Medical School
- John Rush, MD, Duke University School of Medicine
- Sidney Zisook, MD, University of California, San Diego
The event may be accessed at through the Investor Relations section of the Company’s website or by clicking here.
Please connect at least 15 minutes prior to the live webcast to register and ensure adequate time for any software download that may be needed to access the event.
A replay and archived edition of the event will be available through the Investor Relations section of the Company’s website for [30 days] following the event.
About COMPASS Pathways
COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we have completed a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. This was the largest randomised, controlled, double-blind psilocybin therapy clinical trial ever conducted, and our topline data showed a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single high dose of COMP360 psilocybin with psychological support. We are also running phase II clinical trials of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD) and anorexia nervosa. COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the US. Our vision is a world of mental wellbeing. www.compasspathways.com
Availability of other information about COMPASS Pathways
Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Media: Amy Lawrence, email@example.com, +44 7813 777 919
Investors: Stephen Schultz, firstname.lastname@example.org, +1 401 290 7324